| Literature DB >> 30555745 |
Li-Ming Zhang1,2, Hou-Yu Ju1,2, Yun-Teng Wu1,2, Wei Guo1,2, Lu Mao1,2, Hai-Long Ma1,2, Wei-Ya Xia3, Jing-Zhou Hu1,2, Guo-Xin Ren1,2.
Abstract
ANRIL (CDKN2B antisense RNA 1, CDKN2B-AS1) is involved in the progression of various cancers. However, its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. In this study, we found that ANRIL expression was upregulated in HNSCC and correlated with tumor progression. Further functional analysis showed that knockdown of ANRIL significantly inhibited proliferation in vivo and in vitro. ANRIL functioned as a ceRNA (competing endogenous RNAs) for miR-125a-3p and upregulated FGFR1 (fibroblast growth factor receptor-1), which could promote tumor growth. Moreover, we confirmed that ANRIL promoted HNSCC activity via FGFR1 with a FGFR1 inhibitor in vivo and in vitro. Thus, it could be concluded that ANRIL promoted the progression of HNSCC via miR-125a-3p/FGFR1/MAPK signaling, which might provide a new target for the diagnosis and treatment of HNSCC.Entities:
Keywords: ANRIL; FGFR1; Head and neck squamous cell carcinoma; miR-125a-3p; proliferation
Year: 2018 PMID: 30555745 PMCID: PMC6291644
Source DB: PubMed Journal: Am J Cancer Res ISSN: 2156-6976 Impact factor: 6.166